Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study. (Q51336746)

From Wikidata

Jump to navigation Jump to search

scientific article published on 26 May 2012

Language	Label	Description	Also known as
English	Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study.	scientific article published on 26 May 2012

Statements

scholarly article

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study. (English)

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

author name string

Atsushi Wakita

1

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

Shigeki Ohtake

2

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

Satoru Takada

3

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

Fumiharu Yagasaki

4

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

Hirokazu Komatsu

5

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

Yasushi Miyazaki

6

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

Kohmei Kubo

7

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

Yukihiko Kimura

8

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

Akihiro Takeshita

9

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

Yoko Adachi

10

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

Hitoshi Kiyoi

11

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

Takuhiro Yamaguchi

12

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

Minoru Yoshida

13

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

Kazunori Ohnishi

14

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

Shuichi Miyawaki

15

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

Tomoki Naoe

16

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

Ryuzo Ueda

17

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

Ryuzo Ohno

18

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

publication date

26 May 2012

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

International Journal of Hematology

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

96

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

1

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

84-93

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

https://scigraph.springernature.com/pub.10.1007/s12185-012-1105-y

0 references

Management of acute myeloid leukemia in elderly patients

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1105-Y

21 January 2018

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1105-Y

21 January 2018

Age and acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1105-Y

21 January 2018

Acute myeloid leukemia and myelodysplastic syndromes in older patients

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1105-Y

21 January 2018

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1105-Y

21 January 2018

Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1105-Y

21 January 2018

Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1105-Y

21 January 2018

Bestatin, an aminopeptidase inhibitor with a multi-pharmacological function

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1105-Y

21 January 2018

"Proving the null hypothesis" in clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1105-Y

21 January 2018

Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1105-Y

21 January 2018

A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1105-Y

21 January 2018

Treatment of adult acute non-lymphoblastic leukemia using intermittent combination chemotherapy with daunomycin, cytosine arabinoside, 6-mercaptopurine and prednisolone-DCMP two step therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22639053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22639053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunomodulatory and therapeutic properties of bestatin in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/22639053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose daunorubicin in older patients with acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22639053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of bestatin on syngeneic tumors in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/22639053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG)

1 reference

https://pubmed.ncbi.nlm.nih.gov/22639053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B

1 reference

https://pubmed.ncbi.nlm.nih.gov/22639053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22639053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

How high can we increase complete remission rate in adult acute myeloid leukemia?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22639053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experience.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22639053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

1 reference

https://pubmed.ncbi.nlm.nih.gov/22639053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/22639053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22639053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/22639053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ubenimex in the treatment of acute nonlymphocytic leukemia in adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/22639053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22639053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12185-012-1105-Y

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/22639053

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51336746&oldid=1534947973"